<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17669</article-id><article-id pub-id-type="doi">10.15789/2220-7619-TIW-17669</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Tumor infection with human herpes viruses and features of peripheral blood lymphocyte subset composition in patients with uveal melanoma</article-title><trans-title-group xml:lang="ru"><trans-title>Инфицированность опухоли вирусами герпеса человека и особенности субпопуляционного состава лимфоцитов периферической крови у пациентов с увеальной меланомой</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Svetlova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Светлова</surname><given-names>Елена Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Virologist, Laboratory of Virology and Microbiology, Department of Immunology and Virology</p></bio><bio xml:lang="ru"><p>врач-вирусолог вирусологической микробиологической лаборатории отдела иммунологии и вирусологии</p></bio><email>qr888@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Balatskaya</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Балацкая</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Leading Researcher, Head of the Department of Immunology and Virology</p></bio><bio xml:lang="ru"><p>к.б.н., ведущий научный сотрудник, начальник отдела иммунологии и вирусологии</p></bio><email>qr888@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kulikova</surname><given-names>I. G.</given-names></name><name xml:lang="ru"><surname>Куликова</surname><given-names>И. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Biologist, Laboratory of Virology and Microbiology, Department of Immunology and Virology</p></bio><bio xml:lang="ru"><p>биолог вирусологической микробиологической лаборатории отдела иммунологии и вирусологии</p></bio><email>qr888@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Saakyan</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Саакян</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>RAS Corresponding Member, DSc (Medicine), Professor, Head of the Department of Ophthalmooncology and Radiology</p></bio><bio xml:lang="ru"><p>член-корреспондент РАН, д.м.н., профессор, начальник отдела офтальмоонкологии и радиологии</p></bio><email>qr888@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Svirina</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Свирина</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD Student, Department of Ophthalmooncology and Radiology</p></bio><bio xml:lang="ru"><p>аспирант отдела офтальмоонкологии и радиологии</p></bio><email>qr888@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Andryushin</surname><given-names>A. E.</given-names></name><name xml:lang="ru"><surname>Андрюшин</surname><given-names>А. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Researcher, Department of Immunology and Virology</p></bio><bio xml:lang="ru"><p>научный сотрудник отдела иммунологии и вирусологии отдела иммунологии и вирусологии</p></bio><email>qr888@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Myakoshina</surname><given-names>E. B.</given-names></name><name xml:lang="ru"><surname>Мякошина</surname><given-names>Е. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>DSc (Medicine), Researcher, Department of Ophthalmooncology and Radiology</p></bio><bio xml:lang="ru"><p>д.м.н., научный сотрудник отдела офтальмоонкологии и радиологии</p></bio><email>qr888@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Moscow Helmholtz Research Сentre of Eye Diseases</institution></aff><aff><institution xml:lang="ru">ФГБУ НМИЦ глазных болезней им. Гельмгольца</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-04-30" publication-format="electronic"><day>30</day><month>04</month><year>2025</year></pub-date><volume>15</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>79</fpage><lpage>87</lpage><history><date date-type="received" iso-8601-date="2024-05-24"><day>24</day><month>05</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-08-13"><day>13</day><month>08</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Svetlova E.V., Balatskaya N.V., Kulikova I.G., Saakyan S.V., Svirina I.V., Andryushin A.E., Myakoshina E.B.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Светлова Е.В., Балацкая Н.В., Куликова И.Г., Саакян С.В., Свирина И.В., Андрюшин А.Е., Мякошина Е.Б.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Svetlova E.V., Balatskaya N.V., Kulikova I.G., Saakyan S.V., Svirina I.V., Andryushin A.E., Myakoshina E.B.</copyright-holder><copyright-holder xml:lang="ru">Светлова Е.В., Балацкая Н.В., Куликова И.Г., Саакян С.В., Свирина И.В., Андрюшин А.Е., Мякошина Е.Б.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/17669">https://iimmun.ru/iimm/article/view/17669</self-uri><abstract xml:lang="en"><p><italic>Introduction.</italic> Currently, a role for human herpes viruses (HHV) in development of ocular oncopathology remains one of the poorly explored issues. An important factor contributing to neoplastic progression is impaired immunosurveillance particularly alterations in quantitative and qualitative composition of the hallmark peripheral blood lymphocyte subsets. The aim of the study was to determine and analyze peripheral blood lymphocyte subset composition in patients with uveal melanoma (UM) assessing human herpes viruses (HHV) infection in tumor material. <italic>Materials and methods.</italic> Biomaterial from 99 patients with uveal tract tumors was examined by real-time polymerase chain reaction (rt-PCR) for DNA presence coupled to herpes virus type 1 and 2 (HSV-1,2), Varicella Zoster virus (VZV), cytomegalovirus (CMV), Epstein–Barr virus (EBV), human herpes virus types 6 and 8 (HHV-6, HHV-8). A total of 231 test samples (tumor tissue (n = 99), blood (n = 132)) were examined. Commercial test-systems of “Vector-Best” (Russia) were used for rt-PCR staging. Peripheral blood lymphocyte subset composition in all patients was studied by laser cytofluorometry on “BD FACSCanto II” flow cytometer. The control group included 33 healthy donors. Statistical data processing was performed using “Biostatd”, “Excel” (t — Student’s t-test, level of statistical significance: p &lt; 0.05) software. <italic>Results.</italic> HHV DNA was detected in the tumor material from 11.3% of patients (n = 11): in 72.7% of cases EBV, in 18.2% — HHV-6. Co-infection with EBV and HHV-6 was detected in 1 case (retinal pigment epithelium adenocarcinoma). According to the PCR data, patients were divided into 2 groups based on tumor infectivity: Group 1 — HHV+ and Group 2 — HHV–. Patients from HHV+ group had significantly increased and decreased total T-cell (CD3<sup>+</sup>) and NK-cell count, respectively, compared with patients lacking HHV DNA in tumor tissue and control group. Individual analysis of frequencies deviating from normal range showed that HHV+ group had 3-fold more often increased percentage of CD3<sup>+</sup> lymphocytes, 2-fold more often absolute count of CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>+</sup> cells, 2.3-fold more often rise in CD4<sup>+</sup>/CD8<sup>+</sup> ratio. <italic>Conclusion.</italic> The obtained data suggest that viruses may be involved in maintaining immunological resistance in tumor patients.</p></abstract><trans-abstract xml:lang="ru"><p><italic>Введение.</italic> Роль вирусов группы герпеса (HHV) в развитии глазной онкопатологии в настоящее время остается одним из малоизученных вопросов. Важным фактором, способствующим неопластической прогрессии, является ослабление системы иммунологического надзора и, в частности, нарушения в количественном и качественном составе основных субпопуляций лимфоцитов периферической крови. Цель: определение и анализ субпопуляционного состава лимфоцитов периферической крови у пациентов с УМ в зависимости от инфицированности материала опухолей вирусами герпеса человека (HHV). <italic>Материалы и методы.</italic> Биоматериал 99 пациентов с опухолями увеального тракта обследован методом полимеразной цепной реакции в реальном времени (ПЦР-РВ) на наличие ДНК вирусов герпеса 1 и 2 типов (HSV-1,2), вируса Varicella Zoster (VZV), цитомегаловируса (CMV), вируса Эпшейна–Барр (EBV), вирусов герпеса человека 6 и 8 типов (HHV-6, HHV-8). Всего исследована 231 тест-проба (ткань опухоли (n = 99), кровь (n = 132)). Для постановки ПЦР-РВ использовали коммерческие тест-системы ЗАО «Вектор-Бест». Всем пациентам провели исследование субпопуляционного состава лимфоцитов периферической крови методом лазерной цитофлуориметрии на проточном цитометре «BD FACS Canto II». В группу контроля вошли 33 здоровых донора. Статистическая обработка данных выполнена в программах «Biostatd», «Exсel» (t -критерий Стьюдента, уровень статистической значимости: p &lt; 0,05) <italic>Результаты.</italic> ДНК HHV обнаружена в материале опухоли 11,3% пациентов (n = 11): в 72,7% случаев EBV, в 18,2% — HHV-6. В 1 случае (при АПЭС) выявлено сочетанное инфицирование EBV и HHV-6. По результатам ПЦР-обследования в зависимости от инфицированности опухоли пациентов распределили на 2 группы: I группа — HHV+ и II группа — HHV–. У пациентов HHV+ группы обнаружили статистически значимое повышение общего количества Т-клеток (CD3<sup>+</sup>) и снижение NK-клеток в сравнении с пациентами без ДНК возбудителя в ткани опухоли и группой контроля. Индивидуальный анализ частоты сдвигов от нормы показал, что в группе HHV+ в 3 раза чаще встречаются пациенты с повышенными значениями относительного количества CD3<sup>+</sup>-лимфоцитов, в 2 раза чаще абсолютного количества CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>+</sup>-клеток, в 2,3 раза чаще с увеличением соотношения CD4<sup>+</sup>/CD8<sup>+</sup>. <italic>Заключение.</italic> Полученные данные позволяют предположить участие вирусов в поддержании иммунологической резистентности у пациентов с опухолями.</p></trans-abstract><kwd-group xml:lang="en"><kwd>herpes group viruses</kwd><kwd>uveal melanoma</kwd><kwd>polymerase chain reaction</kwd><kwd>lymphocyte subpopulations</kwd><kwd>blood</kwd><kwd>tumor tissue</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>вирусы группы герпеса</kwd><kwd>увеальная меланома</kwd><kwd>ПЦР</kwd><kwd>субпопуляции лимфоцитов</kwd><kwd>кровь</kwd><kwd>ткань опухоли</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Балацкая Н.В., Саакян С.В., Мякошина Е.Б., Куликова И.Г., Кричевская Г.И. Особенности эффекторных субпопуляций лимфоцитов у пациентов с увеальной меланомой при активации и хроническом течении герпесвирусной инфекции // Инфекция и иммунитет. 2021. Т. 11, № 6. C. 1123–1130. [Balatskaya N.V., Saakyan S.V., Myakoshina E.B., Kulikova I.G., Krichevskaya G.I. Features of effector lymphocyte subsets in patients with uveal melanoma in recurrent and chronic herpesvirus infection. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2021, vol. 11, no. 6, pp. 1123–1130. (In Russ.)] doi: 10.15789/2220-7619-FOE-1596</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Давыдова Ю.О., Капранов Н.М., Никифорова К.А., Караваева О.С., Камельских Д.В., Дроков М.Ю., Кузьмина Л.А., Гапонова Т.В., Гальцева И.В., Паровичникова Е.Н. Субпопуляционный состав T-хелперов у больных острыми лейкозами после трансплантации аллогенных гемопоэтических стволовых клеток // Клиническая онкогематология. 2023. Т. 16, № 2. С. 137–145. [Davydova Yu.O., Kapranov N.M., Nikiforova K.A., Karavaeva O.S., Kamelskikh D.V., Drokov M.Yu., Kuzmina L.A., Gaponova T.V., Galtseva I.V., Parovichnikova E.N. T-helper subpopulations in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Klinicheskaya onkogematologiya = Clinical Oncohematology, 2023, vol. 16, no. 2, pp. 137–145. (In Russ.)] doi: 10.21320/2500-2139-2023-16-2-137-145</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с. [Malignant neoplasms in Russia in 2022 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskii, A.O. Shakhzadova. Moscow: P.A. Herzen Moscow Research Institute of Oncology — branch of the National Medical Research Center of Radiology of the Ministry of Health of Russia, 2024. 276 p. (In Russ.)]</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Саакян С.В., Мякошина Е.Б., Кричевская Г.И., Слепова О.С., Пантелеева О.Г., Андрюшин А.Е., Хорошилова И.П., Захарова Г.П. Обследование больных увеальной меланомой на наличие герпесвирусных инфекций // Вопросы вирусологии. 2016. Т. 61, № 6. C. 284–287. [Saakyan S.V., Myakoshina E.B., Krichevskaya G.I., Slepova O.S., Panteleeva O.G., Andryushin A.E., Khoroshilova I.P., Zakharova G.P. Testing patients with uveal melanoma for herpesvirus infections. Voprosy virusologii = Problems of Virology, 2016, vol. 61, no. 6, pp. 284–287. (In Russ.)] doi: 10.18821/0507-4088-2016-61-6-284-287</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Human herpesviruses: biology, therapy, and immunoprophylaxis. Eds.: Arvin A., Campadelli-Fiume G., Mocarski E., Moore P.S., Roizman B., Whitley R., Yamanishi K. Cambridge: Cambridge University Press, 2007.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ban Y., Okamoto M., Ogata N. Case of primary intraocular lymphoproliferative disorder caused by Epstein–Barr virus. BMC Ophthalmol., 2020, vol. 20, no. 1: 306. doi: 10.1186/s12886-020-01583-x</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Caraballo Cortés K., Osuch S., Perlejewski K., Pawełczyk A., Kaźmierczak J., Janiak M., Jabłońska J., Nazzal K., Stelmaszczyk-Emmel A., Berak H., Bukowska-Ośko I., Paciorek M., Laskus T., Radkowski M. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus. J. Viral. Hepat., 2019, vol. 26, no. 8, pp. 942–950. doi: 10.1111/jvh.13108</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Chatterjee K., Das P., Chattopadhyay N.R., Mal S., Choudhuri T. The interplay between Epstein-Barr virus (EBV) with the p53 and its homologs during EBV associated malignancies. Heliyon., 2019, vol. 5, no. 11: e02624. doi: 10.1016/j.heliyon. 2019.e02624</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity, 2013, vol. 39, no. 1, pp. 1–10. doi: 10.1016/j.immuni.2013.07.012</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Chijioke O., Müller A., Feederle R., Barros M.H., Krieg C., Emmel V., Marcenaro E., Leung C.S., Antsiferova O., Landtwing V., Bossart W., Moretta A., Hassan R., Boyman O., Niedobitek G., Delecluse H.J., Capaul R., Münz C. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein–Barr virus infection. Cell Rep., 2013, vol. 5, no. 6, pp. 1489–1498 doi: 10.1016/j.celrep.2013.11.041</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol., 2001, vol. 22, no. 11, pp. 633–640. doi: 10.1016/s1471-4906(01)02060-9</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Dunmire S.K., Verghese P.S., Balfour H.H. Jr. Primary Epstein–Barr virus infection. J. Clin Virol., 2018, no. 102, pp. 84–92. doi: 10.1016/j.jcv.2018.03.001</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Güvenç M.G., Midilli K., Ozdoğan A., Inci E., Tahamiler R., Enver O. Detection of HHV-8 and HPV in laryngeal carcinoma. Auris. Nasus. Larynx, 2008, vol. 35, no. 3, pp. 357–362. doi: 10.1016/j.anl.2007.08.006</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Huang X.Q., Mitchell M.S., Liggett P.E., Murphree A.L., Kan-Mitchell J. Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol. Immunother., 1994, vol. 38, no. 6, pp. 399–405. doi: 10.1007/BF01517210</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Huang D., Song S.J., Wu Z.Z., Wu W., Cui X.Y., Chen J.N., Zeng M.S., Su S.C. Epstein–Barr virus-induced VEGF and GM-CSF drive nasopharyngeal carcinoma metastasis via recruitment and activation of macrophages. Cancer Res., 2017, vol. 77, no. 13, pp. 3591–3604 doi: 10.1158/0008-5472.CAN-16-2706</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Uveal melanoma: a model for exploring fundamental cancer biology. Eds.: Jager M.J., Niederkorn J.Y., Ksander B.R. London: Taylor &amp; Francis, 2004. 259 р.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Jones K., Rivera C., Sgadari C., Franklin J., Max E.E., Bhatia K., Tosato G. Infection of human endothelial cells with Epstein–Barr virus. J. Exp Med., 1995, vol. 182, no. 5, pp. 1213–1221. doi: 10.1084/jem.182.5.1213</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Kan-Mitchell J., Liggett P.E., Harel W., Steinman L., Nitta T., Oksenberg J.R., Posner M.R., Mitchell M.S. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer. Immunol. Immunother., 1991, vol. 33, no. 5, pp. 333–340. doi: 10.1007/BF01756599</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kim D.H., Chang M.S., Yoon C.J., Middeldorp J.M., Martinez O.M., Byeon S.J., Rha S.Y., Kim S.H., Kim Y.S., Woo J.H. Epstein–Barr virus BARF1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells. Oncotarget., 2016, vol. 7, no. 50, pp. 82213–82227. doi: 10.18632/oncotarget.10511</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Laichalk L.L., Thorley-Lawson D.A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein–Barr virus in vivo. J. Virol., 2005, vol. 79, no. 2, pp. 1296–1307. doi: 10.1128/JVI.79.2.1296-1307.2005</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Leen A., Meij P., Redchenko I., Middeldorp J., Bloemena E., Rickinson A., Blake N. Differential immunogenicity of Epstein–Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J. Virol., 2001, vol. 75, no. 18, pp. 8649–8659. doi: 10.1128/jvi.75.18.8649-8659.2001</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Li D.K., Chen X.R., Wang L.N., Wang J.H., Li J.K., Zhou Z.Y., Li X., Cai L.B., Zhong S.S., Zhang J.J., Zeng Y.M., Zhang Q.B., Fu X.Y., Lyu X.M., Li M.Y., Huang Z.X., Yao K.T. Exosomal HMGA2 protein from EBV-positive NPC cells destroys vascular endothelial barriers and induces endothelial-to-mesenchymal transition to promote metastasis. Cancer. Gene Ther., 2022, vol. 29, no. 10, pp. 1439–1451. doi: 10.1038/s41417-022-00453-6</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>López-Montañés M., Alari-Pahissa E., Sintes J., Martínez-Rodríguez J.E., Muntasell A., López-Botet M. Antibody-dependent NK cell activation differentially targets EBV-infected cells in lytic cycle and bystander B lymphocytes bound to viral antigen-containing particles. J. Immunol., 2017, vol. 199, no. 2, pp. 656–665. doi: 10.4049/jimmunol.1601574</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Ma J., Usui Y., Takeuchi M., Okunuki Y., Kezuka T., Zhang L., Mizota A., Goto H. Human uveal melanoma cells inhibit the immunostimulatory function of dendritic cells. Exp. Eye Res., 2010, vol. 91, no. 4, pp. 491–499. doi: 10.1016/j.exer.2010.06.025</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Millan M.T., Natkunam Y., Clarke-Katzenberg R., Desai D., Prapong W., So S.K., Esquivel C.O., Sibley R., Ferran C., Martinez O.M. Epstein–Barr virus infection is associated with endothelial Bcl-2 expression in transplant liver allografts. Transplantation, 2002, vol. 73, no. 3, pp. 465–469. doi: 10.1097/00007890-200202150-00023</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Mittra R.A., Pulido J.S., Hanson G.A., Kajdacsy-Balla A., Brummitt C.F. Primary ocular Epstein–Barr virus-associated non-Hodgkin’s lymphoma in a patient with AIDS: a clinicopathologic report. Retina, 1999, vol. 19, no. 1, pp. 45–50. doi: 10.1097/00006982-199901000-00007</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Münz C., Bickham K.L., Subklewe M., Tsang M.L., Chahroudi A., Kurilla M.G., Zhang D., O’Donnell M., Steinman R.M. Human CD4(+) T lymphocytes consistently respond to the latent Epstein–Barr virus nuclear antigen EBNA1. J. Exp Med., 2000, vol. 191, no. 10, pp. 1649–1660. doi: 10.1084/jem.191.10.1649.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Murray P.G., Young L.S. An etiological role for the Epstein–Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood. 2019, vol. 134, no. 7, pp. 591–596. doi: 10.1182/blood.2019000568</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Mygatt G.J., Singhal A., Sukumar G., Dalgard C.L., Kaleeba J.A.R. Oncogenic herpesvirus HHV-8 promotes androgen-independent prostate cancer growth. Cancer. Res., 2013, vol. 73, no. 18, pp. 5695–5708. doi: 10.1158/0008-5472.CAN-12-4196</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Orange J.S. Natural killer cell deficiency. J. Allergy Clin Immunol., 2013, vol. 132, no. 3, pp. 515–525. doi: 10.1016/j.jaci.2013.07.020</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Paludan C., Schmid D., Landthaler M., Vockerodt M., Kube D., Tuschl T., Münz C. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science, 2005, vol. 307, no. 5709, pp. 593–596. doi: 10.1126/science.1104904</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Parrot T., Oger R., Allard M., Desfrançois J., Raingeard de la Blétière D., Coutolleau A., Preisser L., Khammari A., Dréno B., Delneste Y., Guardiola P., Fradin D., Gervois N. Transcriptomic features of tumour-infiltrating CD4lowCD8high double positive αβ T cells in melanoma. Sci Rep., 2020, vol. 10, no. 1: 5900 doi: 10.1038/s41598-020-62664-x</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Quandt D., Rothe K., Scholz R., Baerwald C.W., Wagner U. Peripheral CD4CD8 double positive T cells with a distinct helper cytokine profile are increased in rheumatoid arthritis. PLoS One, 2014, vol. 9, no. 3: e93293. doi: 10.1371/journal.pone.0093293</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Rahemtullah A., Reichard K.K., Preffer F.I., Harris N.L., Hasserjian R.P. A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma. Am. J. Clin. Pathol. 2006, vol. 126, pp. 805–814. doi: 10.1309/Y8KD32QGRYFN1XQX</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Ran G.H., Lin Y.Q., Tian L., Zhang T., Yan D.M., Yu J.H., Deng Y.C. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct Target Ther., 2022, vol. 7, no. 1: 205 doi: 10.1038/s41392-022-01058-z</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Vaivanijkul J., Boonsiri K. Conjunctival tumor caused by Epstein–Barr virus-related infectious mononucleosis: case report and review of literature. Orbit. 2017, vol. 36, no. 2, pp. 91–94. doi: 10.1080/01676830.2017.1279659</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Wang Z.K., Yang B., Liu H., Hu Y., Yang J.L., Wu L.L., Zhou Z.H., Jiao S.C. Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol. Immunother., 2012, vol. 61, no. 6, pp. 911–916. doi: 10.1007/s00262-011-1158-4</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Weiss R.A., Whitby D., Talbot S., Kellam P., Boshoff C. Human herpesvirus type 8 and Kaposi’s sarcoma. J. Natl. Cancer Inst. Monogr., 1998, no. 23, pp. 51–54.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Wong Y., Meehan M.T., Burrows S.R., Doolan D.L., Miles J.J. Estimating the global burden of Epstein–Barr virus-related cancers. J. Cancer Res. Clin. Oncol., 2022, vol. 148, no. 1, pp. 31–46. doi: 10.1007/s00432-021-03824-y</mixed-citation></ref></ref-list></back></article>
